

GENETRONICS BIOMEDICAL CORP

Form 8-K

February 13, 2003

Table of Contents

**UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION**

Washington, D.C. 20549

**FORM 8-K**

Pursuant to Section 13 or 15(d)  
of the Securities Exchange Act of 1934

January 31, 2003

\_\_\_\_\_  
(Date of Report)

**GENETRONICS BIOMEDICAL CORPORATION**

\_\_\_\_\_  
((Exact name of registrant as specified in its charter))

**Delaware**  
(State or other jurisdiction of  
incorporation)

**0-29608**  
(Commission File Number)

**33-0969592**  
(IRS Employer Identification No.)

11199 Sorrento Valley Road, San Diego California, 92121-1334

\_\_\_\_\_  
(Address of principal executive offices)

(858) 597-6006

\_\_\_\_\_  
(Registrant's telephone number, including area code)

Not Applicable

\_\_\_\_\_  
(Former name or former address, if changed since last report.)

**TABLE OF CONTENTS**

ITEM 2. Acquisition or Disposition of Assets.

Item 7. Financial Statements and Exhibits.

SIGNATURES

EXHIBIT 99.1

---

**Table of Contents****ITEM 2. Acquisition or Disposition of Assets.**

On January 31, 2003, Genetronics Biomedical Corporation (the "Company") completed the sale of substantially all of the properties and assets that are primarily used in its BTX Division to Harvard Bioscience, Inc., a Delaware corporation ("HBI"), for a purchase price of \$3.7 million in cash of which \$3.5 million was paid at the closing and the remaining \$200,000 was deposited in escrow pursuant to an escrow agreement expiring in April 2004. The Company will also receive a royalty on net sales of BTX products above certain sales targets for a period of four years. The assets sold included all equipment and other tangible personal property, inventory, identified contracts, accounts receivable, intellectual property and general intangibles, licenses and authorizations and records and lists primarily used in the BTX Division. HBI also obtained rights to certain intellectual property through a license executed concurrently with the sale. HBI assumed certain of the accounts payable of the BTX Division, certain obligations under the assumed customer contracts, substantially all of the product warranty liabilities of the BTX Division and other specifically identified liabilities. The purchase price was determined by arms-length negotiations between the Company and HBI. On December 23, 2002, Seidman & Co., Inc., an independent financial advisor, delivered its oral opinion to the Company's Board of Directors and December 24, 2002, reaffirmed its opinion in writing, that, as of that date and based on and subject to the matters described in its written letter opinion, the consideration anticipated to be received by the Company as a result of the sale of substantially all of the properties and assets that are primarily used in the BTX Division was fair from a financial point of view to the holders of the Company's common stock.

**Item 7. Financial Statements and Exhibits.**

(a) None.

(b) Pro forma financial information reflecting the sale of the BTX Division is set forth on pages 3 through 6 of this Current Report on Form 8-K.

(c) The following exhibits are attached hereto and incorporated herein by reference.

<b>Exhibit No.</b>	<b>Exhibit Description</b>
2.1	Asset Purchase Agreement dated as of December 24, 2002 entered into by and among the Company, Genetronics, Inc. and Harvard Bioscience, Inc. (incorporated by reference from Exhibit A of the Company's Definitive Proxy Statement filed with the SEC on January 7, 2003).
99.1	Press Release dated February 3, 2003 announcing the disposition.

**Table of Contents**

**UNAUDITED PRO FORMA CONSOLIDATED FINANCIAL STATEMENTS**

The following unaudited pro forma consolidated financial information presents pro forma information for the Company giving effect to the sale of the BTX Division, which occurred on January 31, 2003 (the Transaction). The pro forma consolidated financial information is based upon the historical consolidated financial statements of Genetronics Biomedical Corporation for each of the periods presented. The pro forma information is presented as of September 30, 2002 for balance sheet purposes and for the year ended December 31, 2001 and the interim period ended September 30, 2002 for statement of operations purposes.

The pro forma consolidated balance sheet as of September 30, 2002 has been presented as if the Transaction had occurred on September 30, 2002.

The pro forma consolidated statements of operations for the nine month period ended September 30, 2002 and for the year ended December 31, 2001 have been presented as if the Transaction had occurred at the beginning of each period presented.

The pro forma consolidated financial statements have been prepared by Genetronics Biomedical Corporation and all calculations have been made by Genetronics Biomedical Corporation based upon assumptions considered appropriate by the Company. Because the Transaction closed recently, the pro forma financial information is based upon preliminary estimates which could result in adjustments when the final amounts are determined. The estimates included herein are not expected to differ materially from the amounts included herein.

The pro forma consolidated financial information is unaudited, is presented for informational purposes only and does not necessarily indicate what the actual results of operations would have been had the Transaction occurred on the dates indicated, or what the future operating results or financial position of Genetronics Biomedical Corporation may be.

Table of Contents

**Genetronics Biomedical Corporation**  
**Pro Forma Condensed Consolidated Statement of Operations (Unaudited)**  
**Nine Months Ended September 30, 2002**

	As reported	Disposition Adjustments	Pro Forma
	<hr/>	<hr/>	<hr/>
<b>REVENUE</b>			
Net sales	\$ 2,663,998	\$(2,663,998)	\$ 0
License fee and milestone payments	50,463		50,463
Government grants	0		0
Revenue under collaborative research and development arrangements	62,865		62,865
	<hr/>	<hr/>	<hr/>
Total revenue	2,777,326	(2,663,998)	113,328
	<hr/>	<hr/>	<hr/>
<b>EXPENSES</b>			
Cost of sales	1,128,621	(1,128,621)	0
Research and development	2,016,737	(165,312)	1,851,425
Selling, general and administrative	4,046,025	(1,291,356)	2,754,669
	<hr/>	<hr/>	<hr/>
Total operating expenses	7,191,383	(2,585,289)	4,606,094
	<hr/>	<hr/>	<hr/>
<b>(Loss) income from operations</b>	(4,414,057)	(78,709)	(4,492,766)
<b>Other income (expenses)</b>			
Interest income	28,589		28,589
Interest expense	(4,560)		(4,560)
Foreign exchange loss	0		0
	<hr/>	<hr/>	<hr/>
<b>Net (loss) income</b>	\$ (4,390,028)	\$ (78,709)	\$ (4,468,737)
	<hr/>	<hr/>	<hr/>
<b>Net (loss) income per share basic and diluted</b>	\$ (0.12)		\$ (0.12)
<b>Shares used in calculation of earnings per share</b>			
Basic	37,812,744		37,812,744
Diluted	37,812,744		37,812,744
	<hr/>		<hr/>

Table of Contents

**Genetronics Biomedical Corporation**  
**Pro Forma Condensed Consolidated Statement of Operations (Unaudited)**  
**Nine Months Ended December 31, 2001**

	<u>As reported</u>	<u>Adjustments</u>	<u>Disposition Pro Forma</u>
<b>REVENUE</b>			
Net sales	\$ 3,017,747	\$(3,017,747)	\$ 0
License fee and milestone payments	981		981
Government grants	0		0
Revenue under collaborative research and development arrangements	109,669		109,669
	<u>3,128,397</u>	<u>(3,017,747)</u>	<u>110,650</u>
<b>EXPENSES</b>			
Cost of sales	1,322,763	(1,322,763)	0
Research and development	2,325,045	(246,624)	2,078,421
Selling, general and administrative	5,928,502	(1,956,406)	3,972,096
	<u>9,576,310</u>	<u>(3,525,793)</u>	<u>6,050,517</u>
<b>(Loss) income from operations</b>	(6,447,913)	508,046	(5,939,867)
<b>Other income (expenses) Interest</b>			
<b>income</b>	98,865		98,865
Interest expense	(10,742)		(10,742)
Foreign exchange loss	0		0
	<u>(6,359,790)</u>	<u>508,046</u>	<u>(5,851,744)</u>
Unrealized gain on short-term investment/reclassification of loss	(2,152)		(2,152)
	<u>\$ (6,361,942)</u>	<u>\$ 508,046</u>	<u>\$ (5,853,896)</u>
<b>Net (loss) income per share basic and diluted</b>	\$ (0.19)		\$ (0.17)
<b>Shares used in calculation of earnings per share</b>			
<b>Basic</b>	33,759,404		33,759,404
<b>Diluted</b>	<u>33,759,404</u>		<u>33,759,404</u>

Table of Contents

**Genetronics Biomedical Corporation**  
**Pro Forma Condensed Consolidated Balance Sheet (Unaudited)**  
**As of September 30, 2002**

	<u>As Reported</u>	<u>Disposition Adjustments(1)</u>	<u>Pro Forma</u>
<b>Assets</b>			
<b>Current</b>			
Cash and cash equivalents	\$ 1,364,982	\$ 3,700,000	\$ 5,064,982
Short term investments	994,260		994,260
Accounts receivable, net	628,388	(619,488)	8,900
Inventories	758,622	(758,622)	0
Prepaid expenses and other	30,030		30,030
	<u>3,776,282</u>	<u>2,321,890</u>	<u>6,098,172</u>
<b>Total current assets</b>	3,776,282	2,321,890	6,098,172
Fixed assets, net	421,080	(55,339)	365,741
Other assets, net	2,354,154		2,354,154
	<u>2,354,154</u>	<u>2,354,154</u>	<u>2,354,154</u>
<b>Total assets</b>	<u>\$ 6,551,516</u>	<u>\$ 2,266,551</u>	<u>\$ 8,818,067</u>
<b>LIABILITIES AND STOCKHOLDERS' EQUITY</b>			
<b>Current</b>			
Accounts payable and accrued expenses	\$ 1,020,903	\$ 91,905	\$ 1,112,808
Current portion of obligations under capital leases	21,969		21,969
Deferred revenue	201,608		201,608
	<u>1,244,480</u>	<u>91,905</u>	<u>1,336,385</u>
<b>Total current liabilities</b>	1,244,480	91,905	1,336,385
Obligations under capital leases	3,873		3,873
Deferred rent	36,875		36,875
	<u>1,285,228</u>	<u>91,905</u>	<u>1,377,133</u>
<b>Total liabilities</b>	1,285,228	91,905	1,377,133
<b>Stockholders' equity Common</b>			
<b>Stock, \$0.001 par value</b>	40,173		40,173
Additional paid-in-capital	53,259,725		53,259,725
Special warrants	3,853,177		3,853,177
Receivables from executive/stockholders for stock purchase	(33,042)		(33,042)
Cumulative translation adjustment	(101,997)		(101,997)
Accumulated deficit	(51,751,748)	2,174,646	(49,577,102)
	<u>5,266,288</u>	<u>2,174,646</u>	<u>7,440,934</u>
<b>Total stockholders' equity</b>	5,266,288	2,174,646	7,440,934
	<u>5,266,288</u>	<u>2,174,646</u>	<u>7,440,934</u>
<b>Total liabilities and stockholders' equity</b>	<u>\$ 6,551,516</u>	<u>\$ 2,266,551</u>	<u>\$ 8,818,067</u>

(1) Includes accrual of \$330,000 for estimated closing costs.



**Table of Contents**

**SIGNATURES**

Pursuant to the requirements of the Securities and Exchange Act of 1934, the Registrant has duly caused this Report to be signed on its behalf by the undersigned hereunto duly authorized.

**GENETRONICS BIOMEDICAL  
CORPORATION**

DATED: February 13, 2003

By: /s/ Peter Kies

Peter Kies  
Chief Financial Officer